Longitudinal study of cerebrospinal fluid amyloid proteins and apolipoprotein E in patients with probable Alzheimer's disease

Neuroscience Letters

Volumn 249, Issue 1, 1998, Pages 21-24

  Pirttilä, Tuula ^a,b   Koivisto, Keijo ^a,c   Mehta, Pankaj D ^d   Reinikainen, Kari ^e   Kim, Kwang S ^d   Kilkku, Olavi ^e   Heinonen, Esa ^e   Soininen, Hilkka ^a   Riekkinen Sr , Paavo ^a   Wisniewski, Henryk M ^d  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c Seinäjoki Central Hospital   (United States)

^d NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^e ORION CORPORATION   (Finland)

Author keywords

Alzheimer's disease; Amyloid protein; Apolipoprotein E; Cerebrospinal Fluid; Diagnostic marker

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E; BIOCHEMICAL MARKER;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; ARTICLE; CLINICAL ARTICLE; DEMENTIA; FEMALE; GENETIC POLYMORPHISM; HUMAN; LONGITUDINAL STUDY; MALE; NERVE DEGENERATION; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; RISK FACTOR;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID BETA-PROTEIN PRECURSOR; APOLIPOPROTEINS E; FEMALE; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; MENTAL STATUS SCHEDULE; SOLUBILITY;

EID: 0032511074     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(98)00381-4     Document Type: Article

References (20)

1. Baskin F., Smith G.M., Fosmire J.A., Rosenberg R.N. Altered apolipoprotein E secretion in cytokine treated human astrocyte cultures. J. Neurol. Sci. 148:1997;15-18.
2. Bertrand P., Poirier J., Oda T., Finch C.E., Pasinetti G.M. Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol. Brain. Res. 33:1995;174-178.
3. Carroll R.T., Lust M.R., Kim K.S., Doyle P.C., Emmerling M.R. An age-realted correlation between levels of β-amyloid precursor protein and β-amyloid in human cerebrospinal fluid. Biochem. Biophys. Res. Commun. 210:1995;345-349.
4. Hyman B.T., Marzloff K., Arriagada P.V. The lack of accumulation of senile plaques or amyloid burden in Alzheimer's disease suggests a dynamic balance between amyloid deposition and resolution. J. Neuropathol. Exp. Neurol. 52:1993;594-600.
5. Lindh M., Blomberg M., Jensen M., Basun H., Lannfelt L., Engvall B., Scharnagel H., Marz W., Wahlund L.O., Cowburn R.F. Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein. Neurosci. Lett. 229:1997;85-88.
6. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 34:1984;939-944.
7. 42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38:1995;643-648.
8. Nakamura T., Shoji M., Harigaya Y., Watanabe M., Hosoda K., Cheung T.T., Shaffer L.M., Golde T.E., Younkin L.H., Younkin S.G., Hirai S. Amyloid β protein levels in cerebrospinal fluid are elevated in early-onset Alzheimer's disease. Ann. Neurol. 37:1994;903-911.
9. Palmert M.R., Usiak M., Mayeux R., Raskind M., Tortellotte W.W., Younkin S.G. Soluble derivatives of the β amyloid protein precursor in cerebrospinal fluid: alterations in normal aging and in Alzheimer's disease. Neurology. 40:1990;1028-1034.
10. Pirttilä T., Kim K.S., Mehta P.D., Frey H., Wisniewski H.M. Soluble amyloid β-protein in the cerebrospinal fluid from patients with Alzheimer's disease, vascular dementia and controls. J. Neurol. Sci. 127:1994;90-95.
11. Pirttilä T., Mehta P.D., Lehtimäki T., Kim K.S., Sersen E.A., Frey H., Nikkari T., Wisniewski H.M. Relationship between apolipoprotein E4 allele and CSF amyloid β-protein in Alzheimer's disease and controls. Neurosci. Res. Commun. 15:1994;201-207.
12. Saunders A.M., Strittmatter W.J., Schmechel D., St. George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., Hulette C., Crain B., Goldgaber D., Roses A.D. Association of apolipoprotein E allele M4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 43:1993;1467-1472.
13. Schmechel D.E., Saunders A.M., Strittmatter W.J., Crain B.J., Hulette C.M., Joo S.H., Pericak-Vance M.A., Goldgaber D., Roses A.D. Increased amyloid β-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. 90:1993;9649-9653.
14. Seubert P., Vigo-Pelfrey C., Esch F., Lee M., Dovey H., Davis D., Shinha S., Schlossmacher M., Whaley J., Swindlehurst C., McCormack R., Wolfert R., Selkoe D., Lieberburg I., Schenk D. Isolation and quantitation of soluble Alzheimer's β-peptide from biological fluids. Nature. 359:1992;325-327.
15. Skoog I., Hesse C., Fredman P., Andreasson L.A., Palmertz B., Blennow K. Apolipoprotein E in cerebrospinal fluid in 85-year-old subjects. Arch. Neurol. 54:1997;267-272.
16. Southwick P.C., Yamagata S.K., Echols C.L. Jr., Higson G.J., Neynaber S.A., Parson R.E., Munroe W.A. Assessment of amyloid β protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J. Neurochem. 66:1996;259-265.
17. Stern Y., Albert M., Brandt J., Jacobs D., Tang M.X., Marder K., Bell K., Sano M., Devanand D.P., Bylsma F., Lafleche G. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admissions, and death in Alzheimer's disease: prospective analyses from the 'predictors study'. Neurology. 44:1994;2300-2307.
18. Urakami K., Takahashi K., Okada A., Oshima T., Adachi Y., Nakamura S., Kitaguchi N., Tokushima Y., Yamamoto S., Tanaka S. Clinical course and CSF amyloid β protein precursor having the site of application of the protease inhibitor (APPI) levels in patients with dementia of the Alzheimer type. Dementia. 4:1993;59-60.
19. Vandenplas S., Grobler-Rabie A., Brebner K., Ricketts M., Wallis G., Bester A., Boyd C., Mathew C. Blot hybridization of genomic DNA. J. Med. Genet. 21:1984;164-172.
20. Van Nostrand W.E., Wagner S.L., Shankle W.R., Farrow J.S., Dick M., Rozemuller J.M., Kuiper M.A., Wolters E.C., Zimmerman J., Cotman C.W., Cunningham D.D. Decreased levels of soluble amyloid β-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. Natl. Acad. Sci. 89:1992;2551-2555.